Rifampin as a novel trigger of drug-induced enterocolitis syndrome

IJTLD Open · Published 2026-07-01 · DOI 10.5588/ijtldopen.26.0133

Free full text

Authors (8)

A. Tamborino, G. Liccioli, L. Tomei, E. Chiappini, S. Trapani, F. Mori, L. Galli, E. Venturini

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year

2026

Citation

Tamborino, A., Liccioli, G., Tomei, L., et al. (2026). Rifampin as a novel trigger of drug-induced enterocolitis syndrome. IJTLD Open. https://doi.org/10.5588/ijtldopen.26.0133

Related articles

• Response to the Union’s statement on ongoing conflicts and impact on health services · IJTLD Open · 2026 · Same journal
• Post-market surveillance for literature on QuantiFERON TB Gold Plus: what improvements can artificial intelligence bring? · IJTLD Open · 2026 · Same journal
• Mid-upper arm circumference predicts treatment outcomes in paediatric TB: a cohort study · IJTLD Open · 2026 · Same journal
• A mixed-method study to inform the development of long-acting injectable TB treatments · IJTLD Open · 2026 · Same journal
• Linkage to TB and HIV care for persons who smoke illicit drugs: a prospective cohort study · IJTLD Open · 2026 · Same journal
• Anxiety during active TB and enduring post-TB anxiety-related sequelae · IJTLD Open · 2026 · Same journal
• High-dose linezolid during BPaL implementation for pre-extensively drug-resistant TB or failure/intolerance of rifampicin-resistant TB regimens · IJTLD Open · 2026 · Same journal
• Key operational challenges at a programmatic level to achieve optimal use of the GeneXpert platform · IJTLD Open · 2026 · Same journal
• Innovation and progress towards TB elimination in New South Wales, Australia · IJTLD Open · 2026 · Same journal
• Computer-aided detection thresholds can guide repeat rapid molecular testing in TB screening · IJTLD Open · 2026 · Same journal